Revenio Group Corporation: President & CEO Olli-Pekka Salovaara to work temporarily in the US
Revenio Group Corporation Stock Exchange Release 23 March 2015 at 16.30
President & CEO Olli-Pekka Salovaara to work temporarily in the US The United States is Revenio's most important market area, accounting for over 40% of the Group's net sales. Revenio Group's President & CEO Olli-Pekka Salovaara will be moving to work in their new location in Raleigh, North Carolina, to further boost the Group's market position in the US. This temporary move will have no effect on the Group organization or operating structure, nor on Revenio's Head Office functions in Vantaa, Finland. "The United States is the world's largest market for health technology. Through our presence in this market area we will be able to better support our local distribution network and our own organization, and make them even better. Icare has currently 32 independent sales representatives in the US and we intend to make this network even stronger. Local presence is important also in terms of moving forward the FDA process. The most important reason for my moving to the US is to build a personal relationship with the customer base, our distributors and physicians in decision-making positions," says Mr Salovaara. "Our objective is solid growth in health technology, and my move to the US should result in growth and higher market share both in terms of existing and future products and technologies," he continues. Revenio Group Corporation Olli-Pekka Salovaara CEO For further information, please contact: President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 or US +1-561-413-7559 olli-pekka.salovaara@revenio.fi www.revenio.fi Distribution: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. In addition, Revenio has identified new growth opportunities relating to health tech in which common denominators are screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating margin for continuing operations standing at 27,5%. The Revenio Group Corporation is listed on Nasdaq Helsinki.